Annual report pursuant to Section 13 and 15(d)

Commitments and Contingencies - Additional Information (Details)

v3.20.4
Commitments and Contingencies - Additional Information (Details)
1 Months Ended 3 Months Ended 12 Months Ended
Aug. 17, 2020
USD ($)
Apr. 10, 2015
USD ($)
Feb. 29, 2020
USD ($)
MilestonePayment
Jun. 30, 2019
USD ($)
Mar. 31, 2019
USD ($)
Dec. 31, 2020
USD ($)
Dec. 31, 2020
EUR (€)
Jun. 30, 2021
USD ($)
Dec. 20, 2020
USD ($)
Aug. 31, 2020
USD ($)
Aug. 18, 2020
USD ($)
Dec. 31, 2019
USD ($)
Jun. 30, 2017
USD ($)
Purchase Commitment                          
Supply Commitment [Line Items]                          
Purchase commitment non cancelable and cancelable           $ 6,620,000              
Alkermes Plc | Amendment to Purchase and Sale Agreement                          
Supply Commitment [Line Items]                          
Milestone development earn-out consideration payable                 $ 1,060,000 $ 5,000,000 $ 2,500,000    
Payment for one-time non-refundable and non-creditable fee $ 285,000                        
Collaborative arrangements milestone payments upon achievement of regulatory and sales milestones           $ 13,560,000              
Alkermes Plc | Amendment to Purchase and Sale Agreement | Scenario Forecast                          
Supply Commitment [Line Items]                          
Milestone development earn-out consideration payable               $ 1,440,000          
Alkermes Plc | Amendment to Purchase and Sale Agreement | Contingent Consideration, Third Component                          
Supply Commitment [Line Items]                          
Minimum milestone payments percentage           60.00% 60.00%            
Alkermes Plc | Amendment to Purchase and Sale Agreement | Contingent Consideration, Fourth Component                          
Supply Commitment [Line Items]                          
Maximum royalty payment percentage           30.00% 30.00%            
U.S | Cornell University | Neuromuscular Blocking Agents License Agreement                          
Supply Commitment [Line Items]                          
Regulatory approval and commercialization milestones                         $ 5,000,000
European | Cornell University | Neuromuscular Blocking Agents License Agreement                          
Supply Commitment [Line Items]                          
Regulatory approval and commercialization milestones                         $ 3,000,000
Minimum | Alkermes Plc | Amendment to Purchase and Sale Agreement | Contingent Consideration, Fourth Component                          
Supply Commitment [Line Items]                          
Royalty payment percentage           10.00% 10.00%            
Maximum | Executive Officer                          
Supply Commitment [Line Items]                          
Aggregate annual base salaries of employment agreement           $ 927,000              
Maximum | Alkermes Plc | Amendment to Purchase and Sale Agreement | Contingent Consideration, Fourth Component                          
Supply Commitment [Line Items]                          
Royalty payment percentage           12.00% 12.00%            
Recro | Alkermes Transaction                          
Supply Commitment [Line Items]                          
Collaborative arrangements, milestone payments upon achievement of regulatory and sales milestones   $ 140,000,000                      
Recro | Alkermes Transaction | Regulatory Approval and Net Sales Milestones [Member]                          
Supply Commitment [Line Items]                          
Collaborative arrangements, milestone payments upon achievement of regulatory and sales milestones   $ 60,000,000                      
Collaborative arrangements, milestone payments period   7 years                      
Recro | Alkermes Plc | Amendment to Purchase and Sale Agreement | Alkermes Transaction | Contingent Consideration, First Component                          
Supply Commitment [Line Items]                          
Business acquisition contingent consideration, first milestone payment         $ 5,000,000                
Business acquisition contingent consideration possible milestone payments       $ 5,000,000                  
Recro | Alkermes Plc | Amendment to Purchase and Sale Agreement | Alkermes Transaction | Contingent Consideration, Third Component                          
Supply Commitment [Line Items]                          
Minimum milestone payments percentage           60.00% 60.00%            
Recro | Alkermes Plc | Amendment to Purchase and Sale Agreement | Alkermes Transaction | Contingent Consideration, Fourth Component                          
Supply Commitment [Line Items]                          
Maximum royalty payment percentage           30.00% 30.00%            
Recro | Alkermes Plc | Amendment to Purchase and Sale Agreement | Alkermes Transaction | Milestone Payments Due, Following Regulatory Approval | Contingent Consideration, Second Component                          
Supply Commitment [Line Items]                          
Business acquisition contingent consideration possible milestone payments     $ 5,000,000                    
Recro | Alkermes Plc | Amendment to Purchase and Sale Agreement | Alkermes Transaction | Milestone Payments Due, Beginning on First Anniversary of Regulatory Approval | Contingent Consideration, Second Component                          
Supply Commitment [Line Items]                          
Business acquisition contingent consideration possible milestone payments     $ 45,000,000                    
Business acquisition, contingent consideration, number of equal annual milestone payments | MilestonePayment     7                    
Business acquisition, contingent consideration, equal annual milestone payments     $ 6,400,000                    
Recro | Minimum | Alkermes Plc | Amendment to Purchase and Sale Agreement | Alkermes Transaction | Contingent Consideration, Fourth Component                          
Supply Commitment [Line Items]                          
Royalty payment percentage           10.00% 10.00%            
Recro | Maximum | Alkermes Plc | Amendment to Purchase and Sale Agreement | Alkermes Transaction | Contingent Consideration, Second Component                          
Supply Commitment [Line Items]                          
Business acquisition, contingent consideration, milestone payments due period following regulatory approval     180 days                    
Recro | Maximum | Alkermes Plc | Amendment to Purchase and Sale Agreement | Alkermes Transaction | Contingent Consideration, Fourth Component                          
Supply Commitment [Line Items]                          
Royalty payment percentage           12.00% 12.00%            
Recro | Dexmedetomidine License Agreement                          
Supply Commitment [Line Items]                          
Contingent milestone payments, maximum           $ 25,141,000 € 20,500,000            
Amount of royalty payments due or payable           $ 0              
Recro | Dexmedetomidine License Agreement | Minimum                          
Supply Commitment [Line Items]                          
Percentage of royalty payments           10.00% 10.00%            
Recro | Dexmedetomidine License Agreement | Maximum                          
Supply Commitment [Line Items]                          
Percentage of royalty payments           20.00% 20.00%            
Recro | Fadolmidine License Agreement                          
Supply Commitment [Line Items]                          
Amount of royalty payments due or payable                       $ 0  
Additional contingent milestones payment           $ 14,962,000 € 12,200,000            
Recro | Fadolmidine License Agreement | Minimum                          
Supply Commitment [Line Items]                          
Percentage of royalty payments           10.00% 10.00%            
Recro | Fadolmidine License Agreement | Maximum                          
Supply Commitment [Line Items]                          
Percentage of royalty payments           15.00% 15.00%